Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer

Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer
49%35%20%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 21 • YES 24.8%May 22 • YES 44.5%May 24 • YES 40.7%May 26 • YES 36.7%May 27 • YES 33.3%May 28 • YES 37.2%
Telix Pharmaceuticals (Innovations) Pty Limited ($TLX)
No stock close$10.41$9.88$9.34May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • TLX $10.28May 19 • TLX $10.17May 20 • TLX $10.28May 21 • TLX $10.27May 22 • TLX $9.47May 26 • TLX $9.57May 27 • TLX $9.74

Will this trial show a positive result on overall Survival?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

This is advanced prostate cancer that has spread and keeps growing despite hormone-lowering treatment. Overall survival matters because it asks whether people live longer.

1U.S. burden: 333,830 new cases; 36,320 deaths2Distant-stage survival: 37% at 5 years3Bone spread: About 90%